Cargando…

Evolution of antibody immunity following Omicron BA.1 breakthrough infection

Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Chengzi I., Starr, Tyler N., Zhou, Panpan, Dugan, Haley L., Khalifé, Paul, Song, Ge, Champney, Elizabeth R., Mielcarz, Daniel W., Geoghegan, James C., Burton, Dennis R., Raiees, Andrabi, Bloom, Jesse D., Walker, Laura M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516849/
https://www.ncbi.nlm.nih.gov/pubmed/36172124
http://dx.doi.org/10.1101/2022.09.21.508922
_version_ 1784798793050357760
author Kaku, Chengzi I.
Starr, Tyler N.
Zhou, Panpan
Dugan, Haley L.
Khalifé, Paul
Song, Ge
Champney, Elizabeth R.
Mielcarz, Daniel W.
Geoghegan, James C.
Burton, Dennis R.
Raiees, Andrabi
Bloom, Jesse D.
Walker, Laura M.
author_facet Kaku, Chengzi I.
Starr, Tyler N.
Zhou, Panpan
Dugan, Haley L.
Khalifé, Paul
Song, Ge
Champney, Elizabeth R.
Mielcarz, Daniel W.
Geoghegan, James C.
Burton, Dennis R.
Raiees, Andrabi
Bloom, Jesse D.
Walker, Laura M.
author_sort Kaku, Chengzi I.
collection PubMed
description Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough infection in mRNA-vaccinated individuals. Cross-reactive serum neutralizing antibody and memory B cell (MBC) responses declined by two- to four-fold through the study period. Breakthrough infection elicited minimal de novo Omicron-specific B cell responses but drove affinity maturation of pre-existing cross-reactive MBCs toward BA.1. Public clones dominated the neutralizing antibody response at both early and late time points, and their escape mutation profiles predicted newly emergent Omicron sublineages. The results demonstrate that heterologous SARS-CoV-2 variant exposure drives the evolution of B cell memory and suggest that convergent neutralizing antibody responses continue to shape viral evolution.
format Online
Article
Text
id pubmed-9516849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-95168492022-09-29 Evolution of antibody immunity following Omicron BA.1 breakthrough infection Kaku, Chengzi I. Starr, Tyler N. Zhou, Panpan Dugan, Haley L. Khalifé, Paul Song, Ge Champney, Elizabeth R. Mielcarz, Daniel W. Geoghegan, James C. Burton, Dennis R. Raiees, Andrabi Bloom, Jesse D. Walker, Laura M. bioRxiv Article Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform the development of next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific antibody responses up to six months following Omicron BA.1 breakthrough infection in mRNA-vaccinated individuals. Cross-reactive serum neutralizing antibody and memory B cell (MBC) responses declined by two- to four-fold through the study period. Breakthrough infection elicited minimal de novo Omicron-specific B cell responses but drove affinity maturation of pre-existing cross-reactive MBCs toward BA.1. Public clones dominated the neutralizing antibody response at both early and late time points, and their escape mutation profiles predicted newly emergent Omicron sublineages. The results demonstrate that heterologous SARS-CoV-2 variant exposure drives the evolution of B cell memory and suggest that convergent neutralizing antibody responses continue to shape viral evolution. Cold Spring Harbor Laboratory 2022-09-22 /pmc/articles/PMC9516849/ /pubmed/36172124 http://dx.doi.org/10.1101/2022.09.21.508922 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Kaku, Chengzi I.
Starr, Tyler N.
Zhou, Panpan
Dugan, Haley L.
Khalifé, Paul
Song, Ge
Champney, Elizabeth R.
Mielcarz, Daniel W.
Geoghegan, James C.
Burton, Dennis R.
Raiees, Andrabi
Bloom, Jesse D.
Walker, Laura M.
Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title_full Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title_fullStr Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title_full_unstemmed Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title_short Evolution of antibody immunity following Omicron BA.1 breakthrough infection
title_sort evolution of antibody immunity following omicron ba.1 breakthrough infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516849/
https://www.ncbi.nlm.nih.gov/pubmed/36172124
http://dx.doi.org/10.1101/2022.09.21.508922
work_keys_str_mv AT kakuchengzii evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT starrtylern evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT zhoupanpan evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT duganhaleyl evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT khalifepaul evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT songge evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT champneyelizabethr evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT mielcarzdanielw evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT geogheganjamesc evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT burtondennisr evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT raieesandrabi evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT bloomjessed evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection
AT walkerlauram evolutionofantibodyimmunityfollowingomicronba1breakthroughinfection